Announcements
Trials
Browse
Landscape
Eligibility
Clinical Trials
8 trials
Recent
Start date
Enrollment
Phase 3
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Capecitabine
×
Clear all
Filters
3
NCT06312176
2026-03-13
MK-2870-010
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,200 enrolled
NCT04895358
2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
340 enrolled
NCT03221426
2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3
Completed
1,007 enrolled
25 charts
NCT05152147
2026-02-27
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3
Active not recruiting
920 enrolled
NCT02611960
2023-07-13
Keynote-122
Merck Sharp & Dohme LLC
Phase 3
Completed
233 enrolled
21 charts
NCT02494583
2023-04-13
MK-3475-062
Merck Sharp & Dohme LLC
Phase 3
Completed
763 enrolled
29 charts
NCT04859582
2021-12-16
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3
Withdrawn
NCT02555657
2021-12-10
KEYNOTE-119
Merck Sharp & Dohme LLC
Phase 3
Completed
622 enrolled
26 charts